About: Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19
Creator	Einav, Shirit Saul, Sirle
source	Medline; PMC
abstract	[Image: see text] There is a large global unmet need for effective countermeasures to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19). The development of novel antiviral drugs is expensive and too slow to meet the immediate need. The repurposing of drugs that are approved or are under advanced clinical investigation provides a cost- and time-effective therapeutic solution. This review summarizes the major repurposed approaches that have been proposed or are already being studied in clinical trials for COVID-19. Among these approaches are drugs that aim to reduce SARS-CoV-2 replication by targeting either viral enzymatic functions or cellular factors required for the viral life cycle. Drugs that modulate the host immune response to SARS-CoV-2 infection by boosting it to enhance viral clearance or by suppressing it to prevent excessive inflammation and tissue injury represent another category. Lastly, we discuss means to discover repurposed drugs and the ongoing challenges associated with the off-label use of existing drugs in the context of the COVID-19 outbreak.
has issue date	2020-07-20(xsd:dateTime)
bibo:doi	10.1021/acsinfecdis.0c00343
bibo:pmid	32687696
has license	no-cc
sha1sum (hex)	6cd7f51d9f02a866164581f28cd31b65145e3698
schema:url	https://doi.org/10.1021/acsinfecdis.0c00343
resource representing a document's title	Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19
has PubMed Central identifier	PMC7416635
has PubMed identifier	32687696
schema:publication	ACS Infect Dis
resource representing a document's body	covid:6cd7f51d9f02a866164581f28cd31b65145e3698#body_text
is schema:about of	named entity 'clinical trials' named entity 'drugs' named entity 'large' named entity 'prevent' named entity 'PROPOSED' named entity 'MODULATE' named entity 'ANTIVIRAL DRUGS' named entity 'This' named entity 'clinical investigation' named entity 'summarizes' named entity 'causative' named entity 'RNAi' named entity 'pathogen' named entity 'phase 3 clinical trials' named entity 'SARS-CoV-2' named entity 'IL-6' named entity 'viral load' named entity 'coronaviruses' named entity 'vaccine' named entity 'DAAs' named entity 'niclosamide' named entity 'Japan' named entity 'chymotrypsin' named entity 'MEK1' named entity 'tocilizumab' named entity 'coronavirus disease 2019' named entity 'ongoing' named entity 'repurposed' named entity 'causative agent' named entity 'coronavirus disease 2019' named entity 'antiviral drugs' named entity 'Europe' named entity 'filovirus' named entity 'MERS-CoV' named entity 'COVID' named entity 'COVID-19' named entity 'receptor' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'clinical studies' named entity 'DAAs' named entity 'Nafamostat' named entity 'US Food and Drug Administration' named entity 'ebselen' named entity 'influenza' named entity 'lopinavir/ritonavir' named entity 'malaria' named entity 'adenosine' named entity 'viral infection' named entity 'diltiazem' named entity 'nilotinib' named entity 'viruses' named entity 'ARDS' named entity 'PD1' named entity 'transforming growth factor β' named entity 'protease' named entity 'Camostat' named entity 'antiinflammatory' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'tissue fibrosis' named entity 'viral replication' named entity 'Japan' named entity 'antiviral' named entity 'interleukin 6' named entity 'pegylated' named entity 'ARDS' named entity 'Ebola' named entity 'antiviral drug' named entity 'COVID' named entity 'pulmonary vascular' named entity 'IFN' named entity 'viruses' named entity 'EGFR' named entity 'tyrosine kinase' named entity 'EBOV' named entity 'MERS-CoV' named entity 'lung' named entity 'viral replication' named entity 'DAAs'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software